Regeneron Pharmaceuticals
Tracked across 23 events · 1362 articles · First seen Jan 08, 2025 · Last active Aug 23, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received regulatory approvals for new indications, which is expected to positively impact its revenue and market position.
Feb 24, 2026 · 8 articles
Business
Impact: Regeneron Pharmaceuticals, in collaboration with Sanofi, developed Dupixent and received International — European Commission approval for its use in treating chronic spontaneous urticaria in young children, which is expected to boost its market position and revenue.
Apr 13, 2026 · 8 articles
Business
Impact: Regeneron Pharmaceuticals, Inc. entered a strategic collaboration with Telix Pharmaceuticals Limited to jointly develop and commercialize next-generation radiopharmaceutical therapies, expanding its oncology portfolio and entering the targeted radiopharmaceuticals space.
Apr 12, 2026 · 6 articles
Regulatory
Impact: Regeneron Pharmaceuticals is facing a securities fraud investigation due to allegedly misleading statements about its fianlimab + Libtayo drug trial, which caused its stock to drop sharply after the trial failed.
May 18, 2026 · 7 articles
Business
Impact: Regeneron Pharmaceuticals is establishing a new Global Capability Centre in India — Hyderabad, India, which will expand its global operations and enhance its drug development and digital capabilities.
May 26, 2026 · 8 articles
Regulatory
Impact: Regeneron Pharmaceuticals is under investigation for potential securities fraud and unlawful business practices after its stock price fell significantly due to disappointing Phase 3 trial results for its melanoma treatment.
May 21, 2026 · 7 articles
Regulatory
Regeneron Pharmaceuticals faces multiple securities class action lawsuits filed by several law firms, including Bronstein, Gewirtz & Grossman, LLC, Hagens Berman, The Schall Law Firm, Faruqi & Faruqi, Pomerantz LLP, DJS Law Group, Robbins LLP,…
Impact: Regeneron is the defendant in multiple securities class actions alleging securities fraud related to its failed Phase III Fianlimab-Libtayo trial. The company's stock dropped sharply, wiping out $11 billion in market cap, and it faces potential financial and reputational damage.
Jul 16, 2026 · 182 articles
Business
Impact: Regeneron is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
Tech
Impact: Regeneron Pharmaceuticals developed maftivimab, an experimental treatment prioritized by the World Health Organization for the Bundibugyo strain of Ebola, with supplies already in the Democratic Republic of the Congo.
May 28, 2026 · 6 articles
Accidents
Impact: Regeneron Pharmaceuticals is a key partner in the urgent high-level coordination meeting convened by United States — Centers for Disease Control and Prevention, potentially involved in assessing medical countermeasures for the Ebola outbreak.
May 15, 2026 · 446 articles
Business
Impact: Regeneron Pharmaceuticals, Inc. agreed to purchase shares of Parabilis Medicines' common stock in a concurrent private placement, showing confidence in the company.
Jun 10, 2026 · 7 articles
Tech
Impact: Regeneron Pharmaceuticals partly funds and supports Atara Biotherapeutics in developing therapies for diseases like inflammatory bowel disease, leveraging the Nobel-winning research.
Oct 06, 2025 · 6 articles
Regulatory
Impact: Regeneron Pharmaceuticals is expected to announce a deal with the Donald Trump administration after the holidays.
Dec 19, 2025 · 7 articles
Business
Impact: Regeneron Pharmaceuticals is the developer of Eylea, the reference product for Sun Pharma' newly launched biosimilar AHZANTIVE, which could lead to increased competition.
Jun 04, 2026 · 7 articles
Accidents
Impact: Regeneron Pharmaceuticals has an antibody treatment, a component of Inmazeb, which was approved for the Ebola virus and is being prioritized for clinical trials against the Bundibugyo ebolavirus.
May 18, 2026 · 505 articles
Business
Impact: Regeneron has a strategic collaboration and investment with TriNetX.
Jul 27, 2026 · 6 articles
Regulatory
Impact: Co-developer of injectable PCSK9 inhibitor Praluent; may see reduced demand.
Jul 16, 2026 · 93 articles
Tech
Impact: Regeneron Pharmaceuticals is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.
Apr 17, 2026 · 6 articles
Business
Impact: Regeneron Pharmaceuticals>>> owns the trademark for Eylea, the reference product for Alvogen>>>'s AVT06 biosimilar. The potential market entry of AVT06 could introduce competition to Regeneron Pharmaceuticals>>>'s product.
Jun 04, 2026 · 10 articles
Regulatory
Impact: Holder of Eylea trademark; Alvogen's biosimilar AVT06 targets Eylea, but no direct impact from this event.
Jul 29, 2026 · 7 articles
94
Levi & Korsinsky notified investors of lawsuit Regeneron PharmaceuticalsRegeneron Securities Class...
90
Regeneron Pharmaceuticals disclosed trial failureRegeneron Securities Class...
90
Regeneron Pharmaceuticals lost market capRegeneron Securities Class...
90
Regeneron Pharmaceuticals announced failed endpointRegeneron Securities Class...
90
Bronstein, Gewirtz & Grossman, LLC filed class action Regeneron PharmaceuticalsRegeneron Securities Class...
87
Bleichmar Fonti & Auld LLP filed class action Regeneron PharmaceuticalsRegeneron Securities Class...
85
Regeneron Pharmaceuticals admitted slow event ratesRegeneron Securities Class...
85
Hagens Berman filed lawsuit Regeneron PharmaceuticalsRegeneron Securities Class...
85
Faruqi & Faruqi filed securities class action Regeneron PharmaceuticalsRegeneron Securities Class...
80
Regeneron Pharmaceuticals misled investorsRegeneron Securities Class...
80
Regeneron Pharmaceuticals disclosed protocol alterationRegeneron Securities Class...
80
Pomerantz LLP filed class action Regeneron PharmaceuticalsRegeneron Securities Class...
79
Regeneron Pharmaceuticals announced trial expansionRegeneron Securities Class...
77
Pomerantz LLP investigates claims Regeneron PharmaceuticalsRegeneron Securities Class...
75
The Schall Law Firm filed class action Regeneron PharmaceuticalsRegeneron Securities Class...
75
Robbins LLP filed class action Regeneron PharmaceuticalsRegeneron Securities Class...
70
DJS Law Group filed class action Regeneron PharmaceuticalsRegeneron Securities Class...
70
BFA Law filed class action Regeneron PharmaceuticalsRegeneron Securities Class...
60
Reed Kathrein led investigation Regeneron PharmaceuticalsRegeneron Securities Class...
55
Bronstein, Gewirtz & Grossman, LLC announced lawsuit Regeneron PharmaceuticalsRegeneron Securities Class...
55
Peretz Bronstein announced lawsuit Regeneron PharmaceuticalsRegeneron Securities Class...
50
The Schall Law Firm reminds investors Regeneron PharmaceuticalsRegeneron Securities Class...
45
DJS Law Group reminds investors Regeneron PharmaceuticalsRegeneron Securities Class...
40
Wells Fargo cut price target Regeneron PharmaceuticalsRegeneron Securities Class...
30
Evercore noted protocol amendment Regeneron PharmaceuticalsRegeneron Securities Class...
ERGEN INTELLIGENCE
Track Regeneron Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard